Comments
Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Rosuvastatin calcium tablets indicated for lowering cholesterol levels.
According to a release, the Hyderabad-based Aurobindo is eligible for 180 days of generic drug shared exclusivity and the product has been launched in the US market. Rosuvastatin calcium tablets are the generic version of Crestor tablets of IPR Pharmaceuticals, Inc.
Rosuvastatin calcium tablets had annual sales of around $6.78 billion in the 12 months ending May 2016, according to IMS.
Aurobindo’s scrip gained 3.78 per cent on the Bombay Stock Exchange on Wednesday and was trading at Rs 787.75 at noon.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.